Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114266 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Pei Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sich…. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, ErbB Receptors. Die Arbeit nennt 8 Literaturangaben. Gefördert von: Sichuan University, Sichuan University West China Hospital.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China.
- Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China. Electronic address: caodan@scu.edu.cn.
Förderung
- Sichuan University
- Sichuan University West China Hospital
Zitieren
APA
Zhang, P., Han, Y., Cai, Z., & Cao, D. (2024). Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114266
Vancouver
Zhang P, Han Y, Cai Z, Cao D. Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114266
BibTeX
@article{Zhang2024,
author = {Zhang, Pei and Han, Yihui and Cai, Zhaolun and Cao, Dan},
title = {Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114266}
}
EUVIMED